Welcome to CDC stacks | Can We “Hedge” against the Development of Antiviral Resistance among Pandemic Influenza Viruses? - 4215 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Can We “Hedge” against the Development of Antiviral Resistance among Pandemic Influenza Viruses?
  • Published Date:
    Jun 30 2009
  • Source:
    PLoS Med. 6(6).
Filetype[PDF-72.35 KB]


No Related Documents.
You May Also Like:
  1. Vaccines and Antiviral Drugs in Pandemic Preparedness
    Personal Author:
    Monto, Arnold S.
    Published:
    Jan 2006
    Source:
    Emerg Infect Dis. 12(1):55-60.
    Description:
    While measures such as closing schools and social distancing may slow the effects of pandemic influenza, only vaccines and antiviral drugs are clearly efficacious in preventing infection or treating illness. Unless the pandemic strain closely resembl...
    File Type:
    Filetype[PDF - 76.80 KB]
  2. H275Y Mutant Pandemic (H1N1) 2009 Virus in Immunocompromised Patients
    Personal Author:
    Renaud, Christian; Boudreault, Alexandre A.; Kuypers, Jane; Lofy, Kathryn H.; Corey, Lawrence; Boeckh, Michael J.; Englund, Janet A.;
    Published:
    Apr 2011
    Source:
    Emerg Infect Dis. 17(4):653-660.
    Description:
    Most oseltamivir-resistant pandemic (H1N1) 2009 viruses have been isolated from immunocompromised patients. To describe the clinical features, treatment, outcomes, and virologic data associated with infection from pandemic (H1N1) 2009 virus with H275...
    File Type:
    Filetype[PDF - 420.34 KB]
  3. Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins
    Personal Author:
    Marjuki, Henju; Mishin, Vasiliy P.; Chai, Ning; Tan, Man-Wah; Newton, Elizabeth M.; Tegeris, John; Erlandson, Karl; Willis, Melissa; Jones, Joyce; Davis, Todd; Stevens, James; Gubareva, Larisa V.;
    Published:
    Nov 14 2016
    Source:
    J Virol. 2016; 90(23):10446-10458.
    Description:
    The pandemic threat posed by emerging zoonotic influenza A viruses necessitates development of antiviral agents effective against various antigenic subtypes. Human monoclonal antibody (hMAb) targeting the hemagglutinin (HA) stalk offers a promising a...
    File Type:
    Filetype[PDF - 3.28 MB]
  4. 5'PPP-RNA induced RIG-I activation inhibits drug-resistant avian H5N1 as well as 1918 and 2009 pandemic influenza virus replication
    Personal Author:
    Ranjan, Priya; Jayashankar, Lakshmi; Deyde, Varough; Zeng, Hui; Davis, William G; Pearce, Melissa B; Bowzard, John B; Hoelscher, Mary A; Jeisy-Scott, Victoria; Wiens, Mayim E; Gangappa, Shivaprakash; Gubareva, Larisa; García-Sastre, Adolfo; Katz, Jacqueline M; Tumpey, Terrence M; Fujita, Takashi; Sambhara, Suryaprakash;
    Published:
    May 21 2010
    Source:
    Virol J. 2010; 7:102.
    Description:
    Background : Emergence of drug-resistant strains of influenza viruses, including avian H5N1 with pandemic potential, 1918 and 2009 A/H1N1 pandemic viruses to currently used antiviral agents, neuraminidase inhibitors and M2 Ion channel blockers, under...
    File Type:
    Filetype[PDF - 1.03 MB]
  5. Emerging Infectious Diseases: a 10-Year Perspective from the National Institute of Allergy and Infectious Diseases
    Personal Author:
    Fauci, Anthony S.; Touchette, Nancy A.; Folkers, Gregory K.;
    Published:
    Apr 2005
    Source:
    Emerg Infect Dis. 11(4):519-525.
    Description:
    Although optimists once imagined that serious infectious disease threats would by now be conquered, newly emerging (e.g., severe acute respiratory syndrome [SARS]), reemerging (e.g., West Nile virus), and even deliberately disseminated infectious dis...
    File Type:
    Filetype[PDF - 228.68 KB]